Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443164 | 0.89 | KMT2A (0.72) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL10953367 | 0.83 | KMT2A (0.97) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL11458508 | 0.83 | KMT2A (0.72) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL14062525 | 0.83 | KMT2A (0.72) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL11012435 | 0.83 | ALDH1A1 (0.72) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL14015231 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL4929288 | 0.80 | KMT2A (0.67) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL13988500 | 0.78 | KMT2A (0.66) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL14063365 | 0.78 | ALDH1A1 (0.58) | KMT2AALDH1A1MAPK1MAOBHCRTR1 | |
| SCHEMBL8517287 | 0.77 | KMT2A (0.64) | KMT2AALDH1A1MAPK1MAOBHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824825-A4 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INT INC (BB) | 2009-07-08 | — | — | EP | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| EP-1824825-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | Medicure International Inc. (BB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006045203-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INTERNATIONAL INC. (CA) | 2006-05-04 | — | — | WO | disclosed |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | MEDICURE INTERNATIONAL INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | PNPO, GP6, PFKP | KMT2A 4721/4885ALDH1A1 1958/4885MAPK1 3668/4885 |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | PNPO, GP6, PFKP | KMT2A 4721/4885ALDH1A1 1958/4885MAPK1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.